文献速递类风湿关节炎

法国单中心医院中难治性类风湿关节炎患者的特征

Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究在科chin医院连续纳入320例类风湿关节炎患者,按两种难治性类风湿关节炎(D2TRA)定义分组比较。两种定义下D2TRA患者均更常见低社会经济水平、类风湿因子阳性、间质性肺病、更高DAS28-CRP,且更可能对利妥昔单抗和Janus激酶抑制剂有反应。替代定义组甲氨蝶呤使用率更低(53% vs 64%,P=0.046)。

要点

  • 低社会经济水平、糖尿病、间质性肺病及未联用甲氨蝶呤有助于识别D2TRA。
  • 替代定义组甲氨蝶呤使用率53% vs EULAR定义组64%(P=0.046)。
  • 作者认为将两种TNF抑制剂治疗失败者纳入EULAR定义中的「早期D2TRA」有助于快速识别D2TRA患者。

核心结论

  • 低社会经济水平、糖尿病、间质性肺病和未与甲氨蝶呤联用可识别D2TRA。
  • 作者认为将两种TNF抑制剂治疗失败的患者作为「早期D2TRA」纳入EULAR的D2TRA定义,将有助于快速识别D2TRA患者。

研究设计与样本

  • 研究将科chin医院连续治疗的RA患者按两种D2TRA定义分为D2TRA组和非D2TRA组。
  • 两种定义均将D2TRA定义为至少两种靶向治疗失败的RA,EULAR-D2TRA定义要求作用机制不同,替代D2TRA定义不预先判断作用机制。
  • 共纳入320例连续RA患者。

主要发现

  • 鉴定出76例EULAR-D2TRA和244例非D2TRA患者,以及120例替代D2TRA和200例非D2TRA患者。
  • 两种定义下D2TRA患者较非D2TRA患者更可能有较低社会经济水平、类风湿因子阳性、间质性肺病、更高DAS28-CRP,且更可能对利妥昔单抗和Janus激酶抑制剂有反应。
  • 替代D2TRA组接受甲氨蝶呤的患者更少(53% vs 64%,P=0.046)。
  • 不符合EULAR定义的替代D2TRA患者(n=44)均曾接受两种 successive 一线TNF抑制剂(一种单克隆抗体和一种可溶性受体),且在所有其他特征上与EULAR-D2TRA患者相当。

关键数值与推荐

  • EULAR-D2TRA定义:至少两种作用机制不同的靶向治疗失败的RA。
  • 替代D2TRA定义:至少两种靶向治疗失败的RA,不预先判断作用机制。
  • 替代D2TRA组甲氨蝶呤使用率53% vs EULAR-D2TRA组64%(P=0.046)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the features of difficult-to-treat rheumatoid arthritis (D2TRA) patients using two different definitions according to the previous failure of targeted therapies. METHODS: We stratified consecutive RA patients treated at Cochin Hospital into two groups, a D2TRA group and a non-D2TRA group, according to two definitions of D2TRA. Both definitions defined D2TRA as RAs failing at least two targeted therapies, with a different mechanism of action for the EULAR-D2TRA definition or without prejudging the mechanism of action and for the Alternative D2TRA definition. RESULTS: We included 320 consecutive RA patients. We identified 76 EULAR-D2TRA and 244 non-DTRA patients, and 120 Alternative D2TRA and 200 non-DTRA patients. Compared with non-D2TRA, D2TRA patients from both definitions were more likely to have lower socioeconomic level, positive rheumatoid factor, interstitial lung disease, higher DAS28-CRP and were more likely to respond to rituximab and Janus kinase inhibitors. Although EULAR and Alternative D2TRA patients displayed similar clinical and biological features, they were characterized by different therapeutic profiles. We observed fewer patients receiving methotrexate in the Alternative D2TRA group (53% vs 64%, P = 0.046). Patients with Alternative D2TRA not fulfilling the EULAR definition (n = 44) had all received two successive first-line TNF inhibitors, a monoclonal antibody and a soluble receptor, and were comparable to EULAR-D2TRA patients with regards to all other characteristics. CONCLUSION: Low socioeconomic status, diabetes, interstitial lung disease and absence of combination with methotrexate allow identification of D2TRA. In addition, the inclusion as 'early-D2TRA' of patients failing two TNF inhibitors in the EULAR definition of D2TRA would facilitate the rapid identification of D2TRA patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hecquet S, Combier A, Steelandt A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023. PMID: 36961324. doi:10.1093/rheumatology/kead143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。